General Information
Amylin Adolescent DM2 H80-MC-GWBQ
Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents with Type 2 Diabetes.
| Protocol | H80-MC-GWBQ |
|---|---|
| Identifier | Site Number: 173 |
| UID | c87e801b-1de3-49e7-90e7-e32838189bee |
| Status | Done - Archived |
| Phase | 3 |
| Category | Diabetes Type 2 / Adolescent |
| Launch Year | 2017 |
| NCT Number | - |
| Created | 2016-10-28 15:39 |
| Last Updated | 2016-10-28 15:39 |
Description
No description provided.
Comment
PCRS
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | No | |
| Enrollment Open | No | |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2017-03-14 | No |
| PI Meeting Start | No | |
| PI Meeting End | No | |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | 2018-06-28 | No |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Casaclang, Cecilia | CCasaclang | No |
| Recruiter | Miss, Salomon | SMiss | No |
| Coordinator | Sandoval, Larry | LSandoval | No |
| Regulatory | Perez, Myrna | MPerez | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | Amylin |
|---|---|
| Division | Amylin |
| Team | Amylin |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | IQVIA RDS Inc. |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | Gainsboro |
| Currency | - |
